Latest News — Page 12

Is your healthcare supply business ready for South Africa’s tightened procurement regulations?

The article unpacks recent regulatory changes affecting supplier registration, B-BBEE and local-content rules, tender adjudication transparency, and enhanced audit and contract-management obligations — highlighting compliance risks and practical opportunities to win public contracts.

📌 Read the full piece for a clear compliance checklist and actionable next steps.

#SyenzaNews #regulatoryaffairs #healthcare #governance #healthcarepolicy

Are you ready for the 2026 preferential procurement rules reshaping healthcare supply chains? 🔍

New regulations introduce local-content quotas, revised evaluation scoring, and tougher compliance checks that will affect bidding strategies, pricing and supplier partnerships across pharmaceuticals and medical devices. Suppliers must reassess sourcing, certification and market-access plans to remain competitive and compliant.

Read the full breakdown for timelines, practical next steps and negotiation tips.

#SyenzaNews #healthcare #regulatoryaffairs #MarketAccess #healthcarepolicy

Ready for South Africa’s 2026 procurement shake-up in pharma and medtech? 🇿🇦

New strategic procurement regulations will tighten transparency, prioritise local participation and raise compliance and reporting requirements—reshaping tender evaluation, pricing and market access for suppliers. Learn which parts of your commercial, regulatory and supply strategies need to change now to stay competitive.

Read the full analysis for practical steps and risk/opportunity checklists.

#SyenzaNews #pharmaceuticals #MedTech #MarketAccess #governance

Could a new targeted therapy change the game for PTEN‑deficient prostate cancer? 🔬

The FDA has endorsed TruQap for prostate cancers with PTEN loss, marking a step forward for biomarker‑driven treatment and offering clinicians a precision option backed by positive trial data. ✅

Read the full article to see the trial highlights, regulatory implications, and what this means for patients and market access.

#SyenzaNews #oncology #precisionmedicine #MarketAccess #innovation

Are EU rules helping — or holding back — innovative pharmaceutical SMEs? 🔬

This article summarizes EUCOPE’s analysis of the regulatory hurdles small biotech and pharma companies face and outlines practical recommendations to improve predictability, streamline approval pathways, and support scale-up and market access. It’s a concise guide to what changes could speed drug development and strengthen Europe’s innovation ecosystem.

Read the full piece to see the recommendations and what they mean for founders, regulators, and investors. 👇

#SyenzaNews #pharmaceuticals #regulatoryaffairs #innovation #healthcarepolicy

💡 Are cardiovascular health checks the key to unlocking better health outcomes?

Recent findings reveal that structured, risk-based cardiovascular health checks not only improve diagnosis rates for chronic conditions but also provide significant economic and societal benefits. This comprehensive analysis highlights how targeted programs can enhance early detection and reduce long-term health risks across Europe.

Dive into the full article to discover the evidence-based recommendations and the potential for real-world impact on healthcare strategies!

#SyenzaNews #HealthcareInnovation #HealthEconomics #DigitalTransformation

Is Europe ready for regulatory convergence by 2026? 🚀

Rui Santos and Ivo explore how evolving regulatory frameworks and RAPS-led initiatives are moving Europe toward greater harmonization—highlighting what this means for innovation, market access, and compliance strategies. Their article outlines practical steps life‑science and health‑tech teams can take now to stay ahead of the transition.

Read the full piece to get the timeline, risks, and actionable recommendations for your organization.

#SyenzaNews #regulatoryaffairs #HealthTech #innovation #governance

💡 Are you curious about the financial impact of the Most-Favored-Nation (MFN) drug pricing policy?

This policy could save the U.S. an estimated **$529 billion** over the next decade! By linking drug prices to those of peer nations, MFN not only promises significant savings for states and consumers but also aims to maintain innovation in the pharmaceutical sector.

Dive into the analysis and find out how these projections could reshape health economics and improve patient access to essential medications.

Read more in the full article!

#SyenzaNews #HealthEconomics #HealthcarePolicy

Could a mobile app be the difference between a missed dose and better health outcomes? 📱🌍

Sandoz’s mobile-health initiative is using digital tools and community partnerships to expand access to care, support frontline workers, and improve medication adherence in underserved areas. This piece breaks down the program’s approach, early impact, and lessons for scaling mHealth solutions.

Read the full article to see how this model could reshape community health delivery.

#SyenzaNews #digitalhealth #HealthTech #DigitalTransformation #innovation

Can targeted investment finally unlock equitable access to medical devices across Africa? 🌍🩺

New public‑private capital is strengthening supply chains, regulatory alignment and local partnerships to expand access to diagnostics, therapeutic devices and maintenance services. The piece highlights scalable financing models, last‑mile logistics and workforce training that are accelerating market growth and improving health outcomes.

Read the full article to learn which investors, policies and business models are driving change — and where the next opportunities lie.
#SyenzaNews #medicaldevices #HealthTech #MarketAccess #innovation

🤖 How can patient-centered AI systems transform healthcare?

A recent qualitative study unveils the journey of implementing AI tools aimed at enhancing postpartum depression risk assessments. By gathering insights from patients, professionals, and developers, the research highlights critical strategies for minimizing harm while maximizing utility in healthcare settings.

Dive into the findings and explore how to effectively navigate the complexities of this innovative approach!

#SyenzaNews #AIinHealthcare #HealthcareInnovation #DigitalTransformation

🚀 Are we on the brink of a breakthrough in treating refractory inflammatory bowel disease?

Johnson & Johnson’s JNJ-4804 IBD therapy has shown promising results in recent trials, combining two powerful treatments into one injection and nearly doubling remission rates for patients who have exhausted other options. This innovative therapy could redefine patient care in inflammatory bowel disease management.

Curious about how this could impact the future of treatment? Dive into the full article for a comprehensive look at the findings and upcoming trials!

#SyenzaNews #pharmaceuticals #clinicaltrials #innovation

🌍 How is South Africa shaping the future of health through innovative research?

The South African Medical Research Council is taking strides in addressing critical health challenges by integrating biomedical and social sciences, enhancing vaccine production, and improving HIV management. Under the leadership of CEO Ntobeko Ntusi, these efforts promise to bolster local innovation and scientific capacity.

Don’t miss the chance to dive deeper into their transformative strategies and priorities!

#SyenzaNews #HealthcareInnovation #globalhealth #innovation

Could a national medicines reserve be Portugal’s blueprint for a more resilient health system? 💊🛡️

Portugal is building a strategic medicines reserve and tightening supply-chain and stockpile management to safeguard access during crises, reduce shortages, and protect routine care. The move offers practical lessons on procurement, governance, and resource allocation for other health systems.

Read the full piece to understand the policy design, implementation challenges, and implications for patients and policymakers.

#SyenzaNews #pharmaceuticals #HealthEconomics #healthcarepolicy #resourceallocation

Can faster assessments unlock patient access to high-cost medicines? ⏱️

A Dutch institute has shortened evaluation timelines for high-cost drug reviews by streamlining processes and improving stakeholder coordination, boosting predictability for manufacturers and potentially speeding patient access while keeping evidence standards central.

Read the full article to learn which operational changes were made and what this means for market access and healthcare decision‑making. 🔍

#SyenzaNews #regulatoryaffairs #HealthEconomics #MarketAccess #healthcarepolicy

🔍 Curious about Amgen’s latest financial performance and future outlook?

In their first quarter of 2026, Amgen has shown robust growth with a revenue increase of 6%, driven by strong product sales and an impressive pipeline development. As the company navigates challenges in a competitive landscape, this article dives into key performance highlights and what they mean for future investments.

Explore the full details on Amgen’s financial results and strategic direction!

#SyenzaNews #pharmaceuticals #healthcare #innovation